Invida CEO John Graham On Commercializing Products In Asia: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
On the sidelines of the JP Morgan Healthcare Conference, Graham talks about Menarini’s acquisition of Invida, plans for expansion in China and India, and his favorite non-BRIC emerging markets.
You may also be interested in...
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18
UK specialty drug maker Sinclair signed a collaborative deal Dec. 7 with Singapore-based Invida to commercialize a number of dermatology products in 11 Asian markets. While multinational drug makers are accelerating expansion in Asia, specialty pharmaceutical companies are teaming up with contract sales firms such as Invida to capitalize on increasing demand in the region
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.